LEADER 05321nam 2200661 a 450 001 9910139730203321 005 20240516113244.0 010 $a3-527-64526-8 010 $a1-283-43214-5 010 $a9786613432148 010 $a3-527-64525-X 035 $a(CKB)2550000000079155 035 $a(EBL)843410 035 $a(OCoLC)773567113 035 $a(SSID)ssj0000638221 035 $a(PQKBManifestationID)11354303 035 $a(PQKBTitleCode)TC0000638221 035 $a(PQKBWorkID)10707621 035 $a(PQKB)10101698 035 $a(MiAaPQ)EBC843410 035 $a(Au-PeEL)EBL843410 035 $a(CaPaEBR)ebr10630620 035 $a(CaONFJC)MIL343214 035 $a(PPN)179004980 035 $a(EXLCZ)992550000000079155 100 $a20120927d2012 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aManagement of chemical and biological samples for screening applications /$fedited by Mark Wigglesworth and Terry Wood 205 $a1st ed. 210 $aWeinheim $cWiley-VCH$dc2012 215 $a1 online resource (434 p.) 300 $aDescription based upon print version of record. 311 $a3-527-64527-6 311 $a3-527-32822-X 320 $aIncludes bibliographical references and index. 327 $aManagement of Chemical and Biological Samples for Screening Applications; Contents; Preface; List of Contributors; 1 Introduction to Sample Management; References; 2 Generating a High-Quality Compound Collection; 2.1 Defining Current Screening Collections; 2.2 Design Criteria for Enriching a Compound Collection with Drug-Like Compounds; 2.2.1 Physicochemical Tailoring of a Compound Collection; 2.2.2 Lipophilicity Design Considerations; 2.2.3 Other Physicochemical Roadblocks; 2.2.4 Assessing Risk - from Rule of 5 to Rule of 3/75; 2.2.5 Tools Enabling Desk Top In Silico Design 327 $a2.3 Concluding RemarksReferences; 3 Assessing Compound Quality; 3.1 Introduction; 3.2 Process Quality and Analytical Quality in Compound Management; 3.2.1 Process Quality (QA); 3.2.2 Analytical Quality (Sample QC); 3.3 Identity; 3.4 Purity/Stability; 3.4.1 Measuring Purity; 3.4.2 Determining the Most Appropriate Purity Cut-Off for Solutions; 3.4.3 Stability of Solutions; 3.5 Concentration/Solubility; 3.6 Conclusions; Acknowledgments; References; Further Reading; 4 Delivering and Maintaining Quality within Compound Management; 4.1 Introduction 327 $a4.2 What is Quality from a Compound Management Perspective?4.3 Storage and Delivery of Samples in Solution; 4.4 Intercepting Low Purity; 4.5 Storage and Delivery of Solids; 4.6 Automation Quality Control and Reliability; 4.7 High-Quality Data Management; 4.8 Conclusion; Acknowledgments; References; 5 Obtaining and Maintaining High-Quality Tissue Samples: Scientific and Technical Considerations to Promote Evidence-Based Biobanking Practice (EBBP); 5.1 Introduction; 5.1.1 Current Issues and Impediments to Benchmark Level Biospecimen Research 327 $a5.1.2 The Role of the Research Protocol in Preserving Biospecimen Quality5.1.3 Rationale for Best Practice Integration into Sample Management Procedures and Protocols; 5.2 The Path toward Integration of Evidence-based Biobanking Practice; 5.2.1 Conceptual Foundations of Evidence-based Biobanking Practice; 5.2.2 The Pre- and Post-Acquisition Analytic Variable Relationship to EBBP; 5.2.3 The Biospecimen Lifecycle Concept: a Framework to Aid EBBP Protocol Design; 5.3 Integrating Evidence-based Biobanking Practice into Sample Protocols; 5.3.1 Protocol Planning for EBBP-based Sample Management 327 $a5.3.2 Crucial Scientific and Technical Considerations for EBBP Protocol Design5.3.3 Utilizing Publication Reporting Guidelines to Guide EBBP Protocol Design; 5.4 Final Thoughts and Recommendations; 5.4.1 Proposed Staging System to Qualify EBBP Related Data; 5.4.2 Revisiting Crucial Considerations Related to Implementation of EBBP; 5.4.3 Strategies to Optimize Real-Time Implementation of EBBP; References; 6 Thinking Lean in Compound Management Laboratories; 6.1 The Emergence of 'Lean Thinking'; 6.2 The Application of 'Lean Thinking'; 6.3 Lean Thinking in Drug Discovery 327 $a6.4 A Lean Laboratory Toolbox 330 $aFilling an obvious gap in the scientific literature, this practice-oriented reference is the first to tie together the working knowledge of largescreening centers in the pharmaceutical and biotechnological field. It spans the entire fi eld of this emerging discipline, from compoundacquisition to collection optimization for specific purposes, to technology and quality control. In so doing, it applies two decades of expertise gathered by several large pharmaceutical companies to current and future challenges in high-throughput screening. With its treatment of libraries of small molecules 606 $aPharmaceutical technology 615 0$aPharmaceutical technology. 676 $a615.19 701 $aWigglesworth$b Mark$0891820 701 $aWood$b Terry$cDr.$0287404 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139730203321 996 $aManagement of chemical and biological samples for screening applications$91991730 997 $aUNINA